Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FTC, Catalent and Novo Holdings
Consumer groups ask FTC to block Novo Holdings-Catalent deal
U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk , from acquiring contract drug manufacturer Catalent ,
Consumer and labor groups urge FTC to block Catalent sale to Novo Holdings
The coalition said in a letter sent to the FTC Thursday that the deal could reduce access to GLP-1s, and harm competition in development of cell and gene therapies.
Novo Holdings' $16.5B Catalent buyout in crosshairs as consumer groups ask FTC to block the deal
Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. | A dozen consumer groups and trade unions penned a letter to Lina Khan,
Consumer, labor groups urge FTC to block Catalent sale to Novo Nordisk - report
Five U.S. consumer groups and two big labor unions are pushing for the Federal Trade Commission to block Novo Nordisk Foundation's planned $16.5 billion acquisition of Catalent (NYSE:CTLT), arguing that a deal would hurt competition in weigh-loss drugs.
FiercePharma
23h
EU drug reviewers back Novo Nordisk’s FDA-rejected hemophilia drug, snub PTC’s Translarna again
After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...
2d
on MSN
Is Novo Nordisk A/S (NVO) the Most Promising Biotech Stock According to Hedge Funds?
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...
3d
on MSN
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
9h
Novo Nordisk A/S (NYSE:NVO) Shares Down 0.4% on Analyst Downgrade
Novo Nordisk A/S (NYSE:NVO – Get Free Report)’s share price fell 0.4% during mid-day trading on Friday after BMO Capital Markets lowered their price target on the stock from $160.00 to $156.00. BMO ...
2d
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Novo Nordisk NVO has outperformed the market over the past 10 years by 6.26% on an annualized basis producing an average ...
1d
Novo Nordisk: CHMP Recommends Approval Of Alhemo - Quick Facts
Novo Nordisk announced the European Medicines Agency's CHMP has adopted a positive opinion, recommending approval of Alhemo as the ...
11d
Novo Nordisk settles US patent fight with Viatris over Ozempic
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...
1d
Behind the Scenes of Novo Nordisk's Latest Options Trends
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
BioSpace
1d
It’s Earnings Season. Here’s What to Watch for Following J&J Beat
This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ozempic
Catalent
Wegovy
Jim Cramer
Eli Lilly
Feedback